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Abstract
Programmed death ligand-1 (PD-L1) is an important negative regulator of T cell immune responses via interactions with PD-
1 and CD80. However, PD-L1 can also act as a positive costimulator, but the relevant counterreceptor is not known. We
analyzed the role of PD-L1 in CD8-T cell responses to infection with Listeria monocytogenes (LM) or vesicular stomatitis virus
(VSV). PD-L1 blockade impaired antigen-specific CD8 effector T cell expansion in response to LM, but not to VSV infection,
particularly limiting short-lived effector cell differentiation. Simultaneous CD4-T cell depletion and anti-PD-L1 blockade
revealed that PD-L1 provided costimulation even in the absence of CD4-T cells. Most importantly, specific blockade of PD-L1
binding to CD80 or to PD-1 did not recapitulate PDL-1 blockade. The results suggested that PD-L1 plays an important
costimulatory role for antigen-specific CD8 T cells during LM infection perhaps through a distinct receptor or interaction
epitope.
Citation: Xu D, Fu H-H, Obar JJ, Park J-J, Tamada K, et al. (2013) A Potential New Pathway for PD-L1 Costimulation of the CD8-T Cell Response to Listeria
monocytogenes Infection. PLoS ONE 8(2): e56539. doi:10.1371/journal.pone.0056539
Editor: Ramon Arens, Leiden University Medical Center, The Netherlands
Received November 12, 2012; Accepted January 10, 2013; Published February 11, 2013
Copyright:  2013 Xu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by National Institutes of Health AI41576, AI76457. The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: llefranc@neuron.uchc.edu
Introduction
Optimal T cell activation requires three signals: 1) interaction
between TCR and the cognate peptide-MHC complex, 2) positive
costimulation of antigen-specific T cells to promote expansion and
survival [1]; and 3) cytokines that facilitate T cell differentiation,
expansion, and survival [2]. Besides positive costimulation, there
are coinhibitory signals crucial for maintaining immune system
homeostasis and limiting deleterious inflammatory responses as
well as autoimmunity [3]. The B7:CD28 costimulatory family
consists of both positive and negative costimulatory molecules
including CD28, CTLA4 and their ligands CD80 (B7.1) and
CD86 (B7.2), and programmed death-1 (PD-1) and its ligands PD-
L1 and PD-L2. Programmed death-1 (PD-1) binds to both PD-L1
and PD-L2 and is upregulated after T cell activation which serves
to minimize inflammatory side-effects[4]. PD-1 also acts to limit
immunity during chronic virus infection such that blocking PD-1
or PD-L1 can result in reversal of T cell exhaustion and viral
clearance [5,6]. In a T cell tolerance model, blocking PD-L1
augmented T cell expansion and function as compared to PD-1
blockade[7]. This difference implied the possible existence of a
second receptor for PD-L1, which was subsequently identified as
CD80 [5,8]. In addition, it was recently demonstrated that the PD-
L1:CD80 interaction promotes peripheral tolerance [7].
In contrast to the inhibitory roles played by the PD-1 pathway,
PD-L1 can also serve as a positive costimulator. PD-L1
interactions promote bacterial clearance [9–11], Th1 differentia-
tion and expansion[12] and the development of colitis [13]. In the
current study, we investigated the role of PD-L1 in the regulation
of the endogenous antigen-specific CD8 and CD4 T cell responses
to bacteria and virus infections. We unveiled a costimulatory role
for PD-L1 in the CD8 T cell response to Listeria monocytogenes (LM),
but not to vesicular stomatitis virus (VSV) infection. PD-L1
signaling augmented the proliferation of responding CD8 T cells
and modulated differentiation of the short-lived effector cell subset
via a CD4 T cell independent mechanism. Moreover, PD-L1
signals appeared to be delivered through a PD-1 and CD80
independent pathway, thereby suggesting the possible existence of
an additional PD-L1 ligand.
Methods
Mice and infections
C57BL/6 mice were purchased from the National Cancer
Institute. All animal protocols were approved by the University of
Connecticut Health Center Animal Care Committee. Mice were
infected with 16103 cfu LM-OVA or 16105 pfu of VSV-ova i.v.
mAb treatment
Mice were treated with 200 mg mAb specific for PD-L1
(10F.9G2 [14]), PD-L2 (TY25 [15]), PD-1 (RMP1-14 [16]) or
43H12 (PD-L1-CD80 [7]), i.p. on day -1 and every other day after
infection. CD4 T cell depletion was done by treating mice with
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Figure 1. PD-L1 induction in response to infection. A, PD-L1 expression on CD4 T, CD8 T, and B cells on day 2 after LM or VSV infection. Filled
histogram: naive control. Open histogram: day 2 after LM or VSV i.v. infection. B, Comparison of PD-L1 expression on total CD8 T cells 2 days after LM
or VSV infection. C, Comparison of PD-L1 expression by naı¨ve (CD11alow) and activated/memory (CD11ahigh) CD8 T cells and representative 2-D plot of
CD11a versus PD-L1 expression. Data were analyzed by Student’s t test. (***p,0.001). Gating strategy for T cells is based on CD4, CD8 and CD3
expression. Data are representative of three independent experiments with five mice per group.
doi:10.1371/journal.pone.0056539.g001
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200 mg GK1.5 i.p. 3 days before infection and every other day
after infection.
BrdU incorporation assay
Mice were treated with 1 mg BrdU i.p. 16 hr before sacrificing.
Staining of BrdU incorporation followed the BrdU Flow kit
protocol (Becton-Dickinson).
Flow cytometry
Single-cell suspensions were prepared by collagenase digestion
as previously described [17]. Lymphocytes (56106 cells/ml) were
Figure 2. PD-L1 costimulates the CD8 T cell response to LM
infection. A, OVA257–264/K
b+ splenic CD8 T cell population seven days
after VSV-OVA infection from mice treated with IgG isotype control,
anti-PD-1 (RMP1-14), or anti-PD-L1 (10F.9G2). B, (Top panel) Represen-
tative dot-plot of the CD8 T cell response from control or anti-PD-L1
treated mice eight days after infection. (Bottom panel) Compiled data
showing the total numbers of OVA257–264/K
b+ splenic CD8 T cells eight
days after LM-OVA infection from mice treated with IgG isotype control,
anti-PD-1(RMP1-14), anti-PD-L1(10F.9G2), or anti-PD-L2 (TY25). Data
were analyzed by two-way ANOVA. (*p,0.05. ns, non significant). C,
(Top panel) Representative dot-plot of the splenic CD4 T cell response
from control or anti-PD-L1 treated mice eight days after infection.
(Bottom panel) Compiled data showing the total numbers of LLO190–
201/I–A
b+ CD4 T cells of the spleen from day 8 LM infected mice treated
with anti-PD-L1 (10F.9G2) compared with IgG isotype control. Data
were analyzed by Student’s t test. Data are representative of three
independent experiments with five mice per group.
doi:10.1371/journal.pone.0056539.g002
Figure 3. PD-L1 enhances multifunctional effector CD8 T cell
generation. Mice were infected i.v. with 1000 cfu LM-OVA and treated
with anti-PD-L1 or control IgG. Eight days later splenocytes were
stimulated in vitro with SIINFEKL peptide for 5 hours in the presence of
brefeldin A. Production of IL-2, IFNc and TNF was measured by
intracellular staining and flow cytometry. A. The frequency of
IFNc+TNF+IL-2+ antigen-specific CD8+ T cells. B–D. Comparison of the
mean fluorescent intensity (MFI) of staining for each cytokine. Values
are means +/2 standard error. Data are representative of three
independent experiments with five mice per group. Data were analyzed
by student t test. (*p,0.05, ns, not significant).
doi:10.1371/journal.pone.0056539.g003
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stained with peptide:MHC tetramers, and other antibodies as
indicated. The LLO-I-Ab tetramer [18] was generously provided
by Dr. Marc Jenkins (UMINN).
Statistical analysis
Statistical significance was determined with unpaired t-test. For
bacterial counts statistical significance was determined with a
Mann-Whitney test, and for data containing more than 2 groups, a
one-way ANOVA test was applied by GraphPad Prism.
Results and Discussion
Upregulation of PD-L1 on CD8 T cells after primary LM or
VSV infection
We examined PD-L1 expression after i.v. infection with LM-ova
or VSV-ova. Two days after infection with either pathogen, PD-
L1 was markedly upregulated on bulk CD4 T cells, CD8 T cells,
and B cells (Fig.1A). PD-L1 expression on CD8 T cells peaked
,day 2 post-infection and subsequently declined (Fig. 1B). LM
infection induced higher levels of PD-L1 on bulk CD8 T cells as
compared to levels induced by VSV infection (Fig. 1B). Moreover,
CD11ahigh effector/memory phenotype CD8 T cells expressed
substantially more PD-L1 as compared to their CD11alow naı¨ve
counterparts (Fig. 1C). Indeed, high PD-L1 expression correlated
with high CD11a levels (Fig. 1C). Thus, PD-L1 expression was
transiently upregulated on T cells after LM infection, similar to
other costimulatory molecules [19,20].
PD-L1 blockade inhibits the CD8 T cell response to LM
infection
To test the potential role of the PD-1 axis in the antigen-specific
CD8 T cell response, we treated mice with anti-PD-L1 (10F.9G2),
anti-PD-L2 (TY25), or anti-PD-1 (RMP1-14) blocking mAb
throughout the infection. The pMHCI tetramer-OVA257–264/K
b
was used to identify antigen-specific CD8 T cells on day 8 post
LM-ova or day 7 post-VSV-ova infections, near the peak of the
responses. The VSV-specific CD8 T cell response was not affected
by either anti-PD-L1, –PD-L2, or -PD-1 mAbs (Fig. 2A and data
not shown). In contrast, blocking PD-L1 resulted in an ,80%
inhibition of the anti-LM CD8 T cell response, while PD-L2 or
PD-1 blockade had no effect (Fig. 2B). Interestingly, the LLO190–
201/I-A
b-specific CD4-T cell response was not diminished by PD-
L1 blockade (Fig. 2C), indicating that a loss of CD4 T cell help
could not explain the inhibition of the CD8 T cell response. We
also examined the production of cytokines after PD-L1 blockade.
While the overall number of cytokine producing cells decreased
after PD-L1 blockade, as expected based on the loss of tetramer+
cells, the cells that produced IFNc, TNF, or IL-2 did so at levels
comparable to their normal counterparts (Fig. 3B–D). However,
the percentage of polyfunctional antigen-specific CD8 T cells, i.e.
those that produced all three cytokines, was reduced by PD-L1
blockade (Fig. 3A). Thus, PD-L1 controlled both the magnitude
and the functionality of the CD8 T cell response to LM infection.
Effector T cell heterogeneity is a hallmark of CD8 T cell
responses to infections [21]. Based on KLRG1 and IL-7R
expression levels, four populations of effector cells can be
identified: early effector cells (KLRG1- IL-7R-; EEC) that give
rise to the other subsets, short-lived effector cells (KLRG1+ IL-7R-
; SLEC) that do not survive long-term, memory precursor effector
cells (KLRG12 IL-7R+; MPEC) that survive to form the memory
pool, and double positive effector cells (KLRG1+ IL27R+;
DPEC) whose origin is unclear [22]. A number of factors have
been identified that affect the lineage decision toward MPEC vs.
SLEC development [21,23]. We therefore examined whether PD-
L1 played a role in effector subset development in response to LM
infection. Blockade of PD-L1 resulted in a decrease in all effector
subsets with the greatest effect on SLEC generation (Fig. 4A,B).
Moreover, blockade of PD-L1 during LM infection impaired
bacterial clearance, while PD-1 blockade enhanced bacterial
clearance in the spleen and liver (Fig. 5). This finding further
indicated distinct functions for PD-1 and PD-L1 during the anti-
LM response.
To further understand the mechanism of PD-L1 costimulation
we examined early proliferation of antigen-specific CD8 T cells.
To this end, we administered BrdU to infected mice 16hrs before
sacrifice with or without PD-L1 blockade. Incorporation of BrdU
into CD8 T cells was analyzed on day 5 post-infection(Fig. 6A,B).
While most tetramer+ cells from the control mice incorporated
BrdU, fewer cells incorporated BrdU after PD-L1 blockade (Fig.
6A). Furthermore, in those Ova/Kb-specific CD8 T cells that did
incorporate BrdU during PD-L1 blockade the level of incorpora-
tion was reduced (Fig. 6B). Using annexin V staining, no difference
Figure 4. PD-L1 costimulation facilitates SLEC differentiation.
Eight days after LM-OVA infection, SLEC, MPEC, DPEC and EEC
population was analyzed within OVA257–264/K
b+ splenic CD8 T cell
population according to their KLRG1 and IL-7R expression. A,
representative plots of the OVA-specific CD8 T cell response and the
expression of CD127 and KLRG1 by gated tetramer+ cells with or
without PD-L1 blockade. B, Graphs show the compiled proportion of
each subset with or without anti-PD-L1 blockade (SLEC: KLRG1+ IL-7R-;
MPEC: KLRG12, IL27R+; EEC: KLRG12, IL27R2; DPEC: KLRG1+,
IL27R+). Data are representative of three independent experiments
with five mice per group. (*p,0.05, **p,0.01, ***p,0.001, ns, not
significant).
doi:10.1371/journal.pone.0056539.g004
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in apoptosis was observed between the groups (Fig. 6C). Thus, PD-
L1 costimulation operated via enhancement of proliferative
pathways.
PD-L1 costimulates CD8 T cells independent of CD4 T cell
help
PD-L1 preferentially costimulated the CD8 T cell response with
little effect on the CD4 T cell response (Fig. 2). Since the CD8 T
cell response to LM is CD4 T cell dependent [24], we next tested
whether PD-L1 operated independently or cooperatively with
CD4 T cells to augment the CD8 T cell response. To test this, we
blocked PD-L1 separately or in conjunction with CD4 T cell
depletion. While both treatments inhibited the response, anti-PD-
L1 blockade was somewhat more effective than CD4 depletion
(Fig. 7A,B). However, CD4 T cell depletion together with anti-PD-
L1 blockade substantially enhanced the inhibitory effect of either
treatment alone. We further calculated the ratio of antigen-specific
CD8 T cell numbers with or without PD-L1 blockade and CD4 T
cell depletion. The level of inhibition was similar in the presence or
absence of CD4 T cells (Fig. 7B). We noticed that the CD11a
expression on tetramer-negative CD8 T cells appeared to increase
after PD-L1 blockade or CD4 depletion (Fig. 7A). However, the
total number of splenic CD11ahigh CD8 T cells was not different
between the groups (Fig. 7C), suggesting that CD11a upregulation
might be non-specific and the result of alterations in the
inflammatory environment. Overall, these data indicated that
both PD-L1 costimulation and CD4 T cell help were required for
optimal CD8 T cell responses to LM infection.
PD-L1 costimulation occurs independent of binding to
known epitopes of PD-1 and CD80
The two known counter-receptors of PD-L1 are PD-1 and
CD80, both of which are well documented to transduce negative
regulatory signals during T cell activation [4,7]. To scrutinize
through which ligand PD-L1 mediated costimulation, we took
advantage of mAbs that specifically block PD-L1 binding to PD-1
(RMP1-14; [16]) or to CD80 (43H12); [7]) and compared their
ability to block the CD8 T cell response during LM infection with
the general inhibition of PD-L1 by 10F.9G2. Surprisingly,
treatment with either RMP1-14 or 43H12 failed to inhibit the
response unlike 10F.9G2 treatment (Fig. 8A,B,C). As an important
positive control, we confirmed the blocking efficiency of 43H12 in
a previously described T cell tolerance model [7]. Treatment with
43H12 greatly enhanced the CD8 T cell response in this model
(data not shown). In addition, the consistent increase in the CD4 T
cell response (data not shown) and enhanced LM clearance (Fig. 5)
with RMP1-14 treatment, indicated that this mAb was also
operating. To insure that the lack of inhibition of the CD8 T cell
response by PD-L1-CD80 blockade (43H12) or PD-1 blockade
(RMP1-14) was not due to compensation through CD80 or PD-1,
we blocked both interactions simultaneously, and found no
inhibition (Fig. 8B). This result was also confirmed by blocking
CD80 with 1G10 (Fig. 8B), which has been shown to block
CD80:PD-1 interaction in vitro[8]. In this experiment, anti-PD-1
treatment resulted in an increase in antigen-specific CD8 T cells
(Fig. 8B), but this was not a consistent finding. Further, to exclude
the possibility that the reduced antigen-specific CD8 T cell
response was caused by a potentiated inhibitory effect via
enhancing PD-L1:PD-1 interaction due to 10F.9G2 mAb treat-
Figure 5. PD-L1 costimulation augments protection against LM infection. Mice were infected with 16105 cfu LM-OVA i.v. and treated with
anti-PD-L1, anti-PD1 or control IgG. The bacterial burden in spleen and liver was analyzed five days later. Data are representative of two independent
experiments with ten mice per group. Data were analyzed by Mann-Whitney test. (*p,0.05, **p,0.01, ns, not significant).
doi:10.1371/journal.pone.0056539.g005
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ment, we blocked PD-1 in conjunction with 10F.9G2 treatment
which again demonstrated that 10F.9G2 blockade of PD-L1
reduced the antigen-specific CD8 T cell response (Fig. 8B). Taken
together, these data suggested that PD-L1 costimulation was
mediated either by binding to an epitope on CD80 or PD-1 that
was not blocked by the available mAbs or by interaction with a
third unknown binding partner.
While much research has focused on the inhibitory effects of the
PD-L1/PD-1 axis, positive costimulatory effects of these and other
predominantly negative regulators have also been described. The
underlying reasons that determine negative versus positive
regulatory events are not clear. Our studies show obvious
contextual cues that control the requirement for PD-L1 mediated
costimulation since the CD8 T cell response to VSV infection was
PD-L1 independent while the response to LM infection integrated
positive signals from PD-L1 costimulation (Fig. 1). Previous work
also showed a role for PD-L1 costimulation in the CD8 T cell
response to LM infection[9,10] that is mediated through
IFNc[11]. Expression of counterligands that direct the choice
between positive and negative regulation may be differentially
controlled during distinct immune responses. While the identity of
the putative third PD-L1 ligand is not yet known, the expression of
this counterreceptor could be disparate between, for example,
VSV and LM infection resulting in the different outcomes of the
CD8 T cell response during PD-L1 blockade that we observed.
This ligand may be distinct from PD-L1 and CD80 or could
represent an interaction between PD-L1 and epitopes on these
molecules that remain accessible in the presence of the available
blocking antibodies. This possibility is supported by the finding
that PD-1-deficient CD8 T cells also exhibit a defect in expansion
in the response to LM infection[11]. Nonetheless, the ultimate
effect was enhancement of the response, indicating a distinction in
the downstream signaling events mediated through PD-L1
interactions which drive negative regulatory events versus the
positive effects described here.
Our data also indicated that both positive and negative
regulation were occurring simultaneously through PD-1 and PD-
Figure 6. PD-L1 augments Ag-specific CD8 T cell proliferation.
A, and B, Brdu incorporation of OVA tetramer+CD8+ T cells. Mice were
administered BrdU 16 hrs before sacrificing on day 5 after i.v. LM
infection with or without PD-L1 blockade. C. Annexin V staining of
tetramer+ cells. Data were analyzed by Student’s t test, (**p,0.01). Data
are representative of three independent experiments with five mice per
group.
doi:10.1371/journal.pone.0056539.g006
Figure 7. PD-L1 costimulation is independent of CD4 T cell
help. A, Representative dot-plots of the antigen-specific CD8 T cell
response eight days after LM-OVA infection following PD-L1 blocking
with or without CD4 T cell depletion. B, The total numbers of OVA257–
264/K
b-specific CD8 T cells or panel C, the total numbers of CD11ahigh
CD8 T cells cells in the spleen from day 8 LM infected mice treated with
IgG isotype control, anti-PD-L1 (10F.9G2), anti-CD4 (GK1.5), or both anti-
PD-L1 and anti-CD4. Comparison of the magnitude of blocking
between PD-L1 blockade with or without CD4 T cell depletion is
shown under the bar graph in panel B. Data are representative of three
independent experiments with five mice per group. ***p,0.001.
doi:10.1371/journal.pone.0056539.g007
CD8 T Cell Costimulation via PD-L1
PLOS ONE | www.plosone.org 6 February 2013 | Volume 8 | Issue 2 | e56539
L1. Thus, while PD-L1 inhibition reduced the overall CD8 T cell
response and decreased protection, PD-1 blockade enhanced
bacterial clearance without consistently affecting the overall
magnitude of the CD8 T cell response. The latter result suggested
that PD-1 may be inhibiting the functional abilities of CD8 T cells
or was affecting innate immune system components. Of additional
significance was the demonstration that PD-L1 costimulation
operated cooperatively, but independently of CD4 T cell help.
Thus, the summation of the positive and negative signaling events
mediated through PD-1/PD-L1 family members served to fine-
tune the overall immune response to provide protection while
maintaining the integrity of the host.
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